- Home
- PETS vs KRRO Comparison
PETS vs KRRO Comparison
Compare PETS & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | KRRO |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 58.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PETS | KRRO |
|---|---|---|
| Price | $3.42 | $8.93 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $3.20 | ★ $74.17 |
| AVG Volume (30 Days) | ★ 1.2M | 205.8K |
| Earning Date | 02-09-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,265,000.00 | $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $5.20 |
| 52 Week High | $5.58 | $55.89 |
Technical Indicators
Market Signals| Indicator | PETS | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 43.49 |
| Support Level | $3.23 | $8.62 |
| Resistance Level | $3.70 | $9.59 |
| Average True Range (ATR) | 0.18 | 0.52 |
| MACD | -0.04 | 0.57 |
| Stochastic Oscillator | 50.87 | 55.26 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.